Intrepid Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-1,511
| Closed | -$881K | – | 68 |
|
|
2020
Q4 | $881K | Sell |
1,511
-176
| -10% | -$100K | 0.44% | 56 |
|
|
2020
Q3 | $870K | Sell |
1,687
-83
| -5% | -$42K | 0.51% | 57 |
|
|
2020
Q2 | $799K | Sell |
1,770
-548
| -24% | -$242K | 0.45% | 61 |
|
|
2020
Q1 | $813K | Sell |
2,318
-2,543
| -52% | -$935K | 0.56% | 51 |
|
|
2019
Q4 | $1.8M | Hold |
4,861
| – | – | 0.97% | 39 |
|
|
2019
Q3 | $1.62M | Buy |
4,861
+156
| +3% | +$50.9K | 0.85% | 37 |
|
|
2019
Q2 | $1.47M | Buy |
4,705
+726
| +18% | +$217K | 0.67% | 41 |
|
|
2019
Q1 | $1.22M | Buy |
3,979
+630
| +19% | +$170K | 0.59% | 40 |
|
|
2018
Q4 | $778K | Hold |
3,349
| – | – | 0.43% | 36 |
|
|
2018
Q3 | $1.05M | Sell |
3,349
-260
| -7% | -$80.7K | 0.4% | 30 |
|
|
2018
Q2 | $1.04M | Sell |
3,609
-55
| -2% | -$15.2K | 0.36% | 31 |
|
|
2018
Q1 | $916K | Buy |
3,664
+255
| +7% | +$64.9K | 0.31% | 29 |
|
|
2017
Q4 | $814K | Sell |
3,409
-1,773
| -34% | -$430K | 0.31% | 28 |
|
|
2017
Q3 | $1.15M | Sell |
5,182
-20,122
| -80% | -$4.53M | 0.47% | 26 |
|
|
2017
Q2 | $5.73M | Sell |
25,304
-560
| -2% | -$122K | 2.24% | 16 |
|
|
2017
Q1 | $5.16M | Sell |
25,864
-8,785
| -25% | -$1.69M | 1.9% | 19 |
|
|
2016
Q4 | $6.32M | Sell |
34,649
-6,455
| -16% | -$1.1M | 2.78% | 16 |
|
|
2016
Q3 | $6.73M | Sell |
41,104
-7,479
| -15% | -$1.14M | 3.17% | 15 |
|
|
2016
Q2 | $6.95M | Sell |
48,583
-16,695
| -26% | -$2.38M | 2.75% | 16 |
|
|
2016
Q1 | $8.93M | Sell |
65,278
-4,024
| -6% | -$528K | 3.52% | 12 |
|
|
2015
Q4 | $9.61M | Sell |
69,302
-3,310
| -5% | -$459K | 3.27% | 13 |
|
|
2015
Q3 | $9.75M | Sell |
72,612
-14,933
| -17% | -$2.15M | 3.08% | 13 |
|
|
2015
Q2 | $13.2M | Sell |
87,545
-64,316
| -42% | -$9.2M | 4.33% | 8 |
|
|
2015
Q1 | $20.5M | Sell |
151,861
-113,488
| -43% | -$14.1M | 6.26% | 3 |
|
|
2014
Q4 | $32M | Sell |
265,349
-29,359
| -10% | -$3.38M | 8.61% | 2 |
|
|
2014
Q3 | $33.4M | Buy |
294,708
+114
| +0% | +$13.5K | 9.05% | 3 |
|
|
2014
Q2 | $35.3M | Buy |
294,594
+6,960
| +2% | +$850K | 8.38% | 2 |
|
|
2014
Q1 | $36.9M | Sell |
287,634
-6,653
| -2% | -$853K | 7.82% | 3 |
|
|
2013
Q4 | $36.4M | Buy |
294,287
+30
| +0% | +$3.66K | 7.11% | 2 |
|
|
2013
Q3 | $34.6M | Sell |
294,257
-21,608
| -7% | -$2.55M | 6.45% | 2 |
|
|
2013
Q2 | $35.4M | Buy |
+315,865
| New | +$37.1M | 6.2% | 2 |
|
Other funds holding BIO
Intrepid Capital Management's BIO Position: Q1 2021 in Review
Intrepid Capital Management sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2021, closing a stake of 1,511 shares — an estimated $881K sold.
Intrepid Capital Management first reported a position in BIO in Q2 2013 and held it in 31 quarters. The position peaked at $36.9M in Q1 2014. 491 funds tracked by Wall St. Rank hold BIO as of Q1 2021.
- Intrepid Capital Management reported no remaining Bio-Rad Laboratories Class A position as of Q1 2021 after selling out during the quarter.
- Intrepid Capital Management sold 1,511 Bio-Rad Laboratories Class A shares in Q1 2021, an estimated $881K.
- Intrepid Capital Management first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and held it in 31 quarters.
- Intrepid Capital Management's Bio-Rad Laboratories Class A position peaked at $36.9M in Q1 2014.
- 491 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2021.
Based on Intrepid Capital Management's 13F filing for Q1 2021, filed 10 May 2021.